Cytosorbents Corporation (NASDAQ:CTSO) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET
Company Participants
Taylor Devlin - Moderator
Phil Chan - CEO
Kathleen Bloch - CFO
Vincent Capponi - President and COO
Irina Kulinets - SVP, Global Regulatory Affairs
Efthymios Deliargyris - Chief Medical Officer
Conference Call Participants
Yuan Zhi - B. Riley
Tom Kerr - Zacks Investment Research
Sean Lee - H.C. Wainwright
Josh Jennings - TD Cowen
Operator
Good afternoon, and welcome to CytoSorbents third quarter 2023 financial and operating results conference call. [Operator Instructions]. Please be advised that the call will be recorded at the company's request. At this time, I'd like to turn the call over to our moderator, Taylor Devlin. Please go ahead, Taylor.
Taylor Devlin
Thank you and good afternoon. Welcome to CytoSorbents' third quarter 2023 financial and operating results conference call. Joining us today from the company are Dr. Phillip Chan, Chief Executive Officer; Vincent Capponi, President and Chief Operating Officer; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH; Christopher Cramer, Senior Vice President of Business Development; and Dr. Irina Kulinets, Senior Vice President of Regulatory.
Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Actual results may differ from results discussed today, and therefore, we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates as of today, November 9, 2023, and we assume no obligation to update these projections in the future as market conditions change.
During today's call, we will have an overview presentation covering the operating and financial highlights for the third quarter of 2023 by Dr. Chan and Ms. Bloch, as well as an update regarding the STAR-T clinical trial by Dr. Deliargyris. Following their presentation, we will open the line to your questions during the live Q&A session with the rest of the management team.
And now it's my pleasure to turn the call over to Dr. Phillip Chan.